Collagen Cross-Linked N-Telopeptide (NTx), Urine
Test Summary
NTx is useful to assess bone resorption in patients with metabolic bone disease. The test is also useful in monitoring therapy to slow or halt osteoporotic bone loss. A decline of 30% or more of NTx over a six-month period suggests effective therapy.
Aliases
- Collagen Cross (urine)
- N-Telopeptide (urine)
- NTX (urine)
Specimen Collection
Special Instructions
N/A
Preferred Specimen
2 mL urine from second morning void submitted in a leak-proof container, no preservative
Minimum Volume
1 mL
Instructions
Do not use preservatives. Acidified specimen is not acceptable. Second morning void urine: Discard the first morning void. Collect the second morning void. Mix well.
Patient Preparation
N/A
Storage
N/A
Transport Temperature
Refrigerated (cold packs)
Specimen Stability
- Room temperature: 72 hours
- Refrigerated: 5 days
- Frozen: 30 days
Limitations
N/A
Other Acceptable Specimens
Random urine, catheterized, or first morning void clean catch, submitted in a leak-proof urine container, no preservative
Unacceptable Specimens
Acidified specimen • Preserved specimen
Order Code
CCNTEL
EPIC (Premier) Code
LAB3840
Includes
Creatinine
CPT Code
- 82523
- 82570
Billing Code
- 670636
- 670635
CPT Statement
Methodology
Chemiluminescence (CL)
FDA Status
FDA Approved
Physician Attestation of Informed Consent
N/A
Testing Laboratory
Quest Diagnostics Nichols Institute
14225 Newbrook Drive
Chantilly VA, 20153
14225 Newbrook Drive
Chantilly VA, 20153
Department
Reference Testing
Reference Range
Collagen Cross-Linked N-Telopeptide (NTx), Random Urine
Results are primarily used for monitoring the response to therapy. A value within the premenopausal reference range does not rule out osteoporosis nor the need for therapy.
Creatinine, Random Urine
| Male | |
| 18-29 Years | 12-99 nM BCE/mM creat |
| 30-59 Years | 9-60 nM BCE/mM creat |
| Female | |
| Premenopausal | 4-64 nM BCE/mM creat |
Creatinine, Random Urine
| ≤6 Months | 2-28 mg/dL |
| 7-11 Months | 2-31 mg/dL |
| 1-2 Years | 2-110 mg/dL |
| 3-8 Years | 2-130 mg/dL |
| 9-12 Years | 2-160 mg/dL |
| >12 Years Male | 20-320 mg/dL |
| >12 Years Female | 20-275 mg/dL |
Setup Schedule / Expected Turnaround Time
Monday - Saturday; Report available: 1 - 2 days
Specimen Collection
Special Instructions
N/A
Preferred Specimen
2 mL urine from second morning void submitted in a leak-proof container, no preservative
Minimum Volume
1 mL
Instructions
Do not use preservatives. Acidified specimen is not acceptable. Second morning void urine: Discard the first morning void. Collect the second morning void. Mix well.
Patient Preparation
N/A
Storage
N/A
Transport Temperature
Refrigerated (cold packs)
Specimen Stability
- Room temperature: 72 hours
- Refrigerated: 5 days
- Frozen: 30 days
Limitations
N/A
Other Acceptable Specimens
Random urine, catheterized, or first morning void clean catch, submitted in a leak-proof urine container, no preservative
Unacceptable Specimens
Acidified specimen • Preserved specimen
Result Information
Methodology
Chemiluminescence (CL)
Testing Laboratory
N/A
Reference Range
Collagen Cross-Linked N-Telopeptide (NTx), Random Urine
Results are primarily used for monitoring the response to therapy. A value within the premenopausal reference range does not rule out osteoporosis nor the need for therapy.
Creatinine, Random Urine
| Male | |
| 18-29 Years | 12-99 nM BCE/mM creat |
| 30-59 Years | 9-60 nM BCE/mM creat |
| Female | |
| Premenopausal | 4-64 nM BCE/mM creat |
Creatinine, Random Urine
| ≤6 Months | 2-28 mg/dL |
| 7-11 Months | 2-31 mg/dL |
| 1-2 Years | 2-110 mg/dL |
| 3-8 Years | 2-130 mg/dL |
| 9-12 Years | 2-160 mg/dL |
| >12 Years Male | 20-320 mg/dL |
| >12 Years Female | 20-275 mg/dL |
Setup Schedule / Expected Turnaround Time
Monday - Saturday; Report available: 1 - 2 days